Carolyn A. Buser

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

37h-index5.1kcitations97works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(34), Microtubule and mitosis dynamics(20), Protein Kinase Regulation and GTPase Signaling(15), Protein Structure and Dynamics(10), Enzyme Structure and Function(10)

Publications97 total

Data from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Data from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 1 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 3 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 6 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 2 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 2 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure Legends 1-6 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 5 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 5 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 3 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 6 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 1 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 4 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure Legends 1-6 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figure 4 from MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
2023Open Access
Supplementary Figures 1-3, Tables 1-2 from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Data from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Data from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Supplementary Figures 1-3, Tables 1-2 from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
page 1 of 5Next →

Frequent Co-authors

George D. Hartman(22), Eileen S. Walsh(20), Kelly Hamilton(19), Robert B. Lobell(18), Nancy E. Kohl(15), Youwei Yan(13), Mark E. Fraley(12), Weikang Tao(12), Hans E. Huber(11), Marc Abrams(10), R. M. Garbaccio(10), Christine Fernandes(10), Keith Rickert(10), Joseph P. Davide(9), Lawrence C. Kuo(8), Paul J. Coleman(8), Theresa M. Williams(7), Laura Sepp‐Lorenzino(7), Samuel Graham(6), David Heimbrook(6)